Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects

• Autor(a) principal: Dewaeles, Edmone
• Data de Publicação: 2022
• Outros Autores: Carvalho, Kévin, Fellah, Sandy, Sim, Jaewon, Boukrout, Nihad, Caillierez, Raphaelle, Ramakrishnan, Hariharan, Van der Hauwaert, Cynthia, Vijaya Shankara, Jhenkruthi, Martin, Nathalie, Massri, Noura, Launay, Agathe, Folger, Joseph K, Schutter, Clémentine de, Larrue, Romain, Loison, Ingrid, Goujon, Marine, Jung, Matthieu, Le Gras, Stéphanie, Gomez-Murcia, Victoria, Faivre, Emilie, Lemaire, Julie, Garat, Anne, Beauval, Nicolas, Maboudou, Patrice, Gnemmi, Viviane, Gibier, Jean-Baptiste, Buée, Luc, Abbadie, Corinne, Glowacki, Francois, Pottier, Nicolas, Perrais, Michael, Cunha, Rodrigo A., Annicotte, Jean-Sébastien, Laumet, Geoffroy, Blum, David, Cauffiez, Christelle
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10316/103690; https://doi.org/10.1172/JCI152924
• topic: G protein–coupled receptors; Nephrology; Pharmacology; Animals; Mice; Cisplatin; Purines; Receptor, Adenosine A2A; Neuralgia; Antineoplastic Agents

Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment.